Related Experiment Video
Updated: Aug 5, 2025

Semi-quantitative Detection of RNA-dependent RNA Polymerase Activity of Human Telomerase Reverse Transcriptase Protein
Published on: June 12, 2018
Deciphering the Functions of Telomerase Reverse Transcriptase in Head and Neck Cancer
Tsung-Jang Yeh1,2,3, Chi-Wen Luo4,5, Jeng-Shiun Du1,2,3
1Division of Hematology & Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 807, Taiwan.
Telomere reverse transcriptase (TERT) promoter mutations are frequent in head and neck cancers (HNCs), particularly in oral squamous cell carcinoma. These TERT mutations are linked to poorer survival outcomes in HNC patients.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- Head and neck cancers (HNCs) represent a significant global health burden with limited predictive biomarkers and unsatisfactory survival rates.
- Telomere maintenance, often reactivated by telomerase reverse transcriptase (TERT), plays a crucial role in cancer development.
- TERT promoter mutations are a key mechanism for telomerase activation in various cancers.
Purpose of the Study:
- To review and summarize the current evidence on TERT promoter mutations in head and neck cancer patients.
- To highlight the prevalence and clinical significance of TERT promoter mutations in HNCs.
- To discuss potential therapeutic strategies targeting telomerase in HNC.
Main Methods:
- Literature review of studies investigating TERT promoter mutations in HNCs.
- Analysis of mutation frequencies and their association with tumor characteristics and patient survival.
- Summary of current therapeutic approaches targeting telomerase.
Main Results:
- TERT promoter mutations, specifically C228T and C250T, are prevalent in HNCs, with frequencies ranging from 11.9% to 64.7%.
- These mutations are more common in oral cavity squamous cell carcinomas (SCCs) and human papillomavirus (HPV)-negative tumors.
- TERT promoter mutations have been associated with poorer survival outcomes in HNC patients.
Conclusions:
- TERT promoter mutations are significant drivers in HNC development and progression.
- Understanding TERT mutation status may aid in predicting prognosis and guiding treatment decisions for HNC patients.
- Further research into targeted therapies against telomerase holds promise for improving HNC outcomes.
More Related Videos
Related Concept Videos
Telomeres and Telomerase
Replicative Cell Senescence
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Replication in Eukaryotes
Many Proteins Orchestrate Replication at the Origin
Eukaryotic replication follows many of the same...
Mechanisms of Retrovirus-induced Cancers
DNA Helicases

